Search Results

ImmunoPrecise Antibodies Ltd. is pleased to announce the appointment of Kristin Taylor as Chief Financial Officer, effective immediately.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand.

InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with ImmunoPrecise Antibodies, an artificial intelligence-driven biotherapeutic research and technology company in what they stated is a landmark collaboration.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effective September 29, 2023. IPA has named Kristin Taylor, MBA, CPA, as interim Chief Financial Officer.